Holen Sie sich die Stockscreener-App
49.54
1.49%
0.723
Schlusskurs vom Vortag:
$48.82
Offen:
$48.58
24-Stunden-Volumen:
615.59K
Relative Volume:
0.99
Marktkapitalisierung:
$3.79B
Einnahmen:
$677.56M
Nettoeinkommen (Verlust:
$59.01M
KGV:
66.47
EPS:
0.7453
Netto-Cashflow:
$136.42M
1W Leistung:
+8.41%
1M Leistung:
+7.33%
6M Leistung:
+29.39%
1J Leistung:
+143.34%
1-Tages-Spanne:
$48.58
$50.03
1-Wochen-Bereich:
$45.99
$50.03
52-Wochen-Spanne:
$18.25
$50.03
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Firmenname
Kiniksa Pharmaceuticals International Plc
Sektor
Telefon
(781) 431-9100
Adresse
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
49.55 | 3.74B | 677.56M | 59.01M | 136.42M | 0.7453 |
TAK
Takeda Pharmaceutical Co Adr
|
18.20 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.24 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.935 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.68 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
555.02 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-09-29 | Eingeleitet | TD Cowen | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2024-05-03 | Eingeleitet | Wells Fargo | Overweight |
| 2020-06-29 | Bestätigt | BofA Securities | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-12-12 | Bestätigt | Wedbush | Outperform |
| 2018-06-19 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten
If You Invested $1,000 in Kiniksa Pharmaceuticals International, plc (KNSA) - Stock Titan
KNSA PE Ratio & Valuation, Is KNSA Overvalued - Intellectia AI
[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity - Stock Titan
Kiniksa (KNSA) CFO receives new options, RSUs and PSUs in 2026 award - Stock Titan
Kiniksa (NASDAQ: KNSA) CEO awarded options, RSUs and PSUs, covers tax - Stock Titan
Kiniksa (KNSA) CMO granted options, RSUs and PSUs in equity awards - Stock Titan
Kiniksa (KNSA) COO receives major equity awards and exercises RSUs - Stock Titan
Kiniksa (KNSA) CAO receives options, RSUs, PSUs and adds to shareholdings - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum - ChartMill
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) stock price, news, quote and history - Yahoo Finance Singapore
KNSA Should I Buy - Intellectia AI
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year HighShould You Buy? - MarketBeat
Hennion & Walsh Asset Management Inc. Trims Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa's discounted P/S ratio reflects investor caution amid weak growth forecasts. Sentiment may not turn bullish unless the company delivers stronger-than-expected revenue growth. - Moomoo
JPMorgan Chase & Co. Has $7.47 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Vanguard realignment leads to 0-share filing for Kiniksa (KNSA) - Stock Titan
SG Americas Securities LLC Has $22.33 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International PLC (KNSA) Trading 3.48% H - gurufocus.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup - ChartMill
Kiniksa raises ARCALYST 2025 revenue guidance to $605M amid strong Q1 performance - msn.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback - Yahoo Finance
Kiniksa Pharmaceuticals International, plc Q4 2025 earnings preview - MSN
Kiniksa Pharmaceuticals International PLC (KNSA) Stock Price Up 3.67% on Mar 16 - GuruFocus
Granahan Investment Management LLC Sells 27,421 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by ArrowMark Colorado Holdings LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires 101,666 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
FMR LLC's Strategic Acquisition of Kiniksa Pharmaceuticals Shares - GuruFocus
Kiniksa (KNSA) CFO sells 36,722 shares after exercising options - Stock Titan
Kiniksa (NASDAQ: KNSA) insider sale notice lists 36,722 shares (Rule 144) - Stock Titan
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - MSN
FMR LLC holds 10.6% of Kiniksa (KNSA) — 4.85M shares reported - Stock Titan
Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again - MSN
Vanguard Group Inc. Trims Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and Bullish Chart Setup - ChartMill
Fisher Asset Management LLC Acquires 180,029 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals CMO Sells Shares Worth Nearly $1.8 Million - TradingView
Kiniksa Pharmaceuticals (KNSA) CMO sells 40K shares after option exercise - Stock Titan
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility - simplywall.st
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Robust Growth Potential With 23% Upside - DirectorsTalk Interviews
Kiniksa (NASDAQ: KNSA) Rule 144 notice: 40,000-share cashless exercise - Stock Titan
KNSA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Prime Example of Affordable Growth (GARP) Investing - ChartMill
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Volatility - Yahoo Finance
KNSA/N Stock Price and Chart — BIVA:KNSA/N - TradingView
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewswire
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts - Benzinga
Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kiniksa Pharmaceuticals International Plc-Aktie (KNSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Paolini John F. | CHIEF MEDICAL OFFICER |
Mar 02 '26 |
Option Exercise |
10.36 |
40,000 |
414,400 |
101,324 |
| Paolini John F. | CHIEF MEDICAL OFFICER |
Mar 02 '26 |
Sale |
44.82 |
40,000 |
1,792,940 |
61,324 |
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):